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Abstract: Molecular epidemiological data on Group A Streptococcus (GAS) infection in Africa is
scarce. We characterized the emm-types and emm-clusters of 433 stored clinical GAS isolates from The
Gambia collected between 2004 and 2018. To reduce the potential for strain mistyping, we used a
newly published primer for emm-typing. There was considerable strain diversity, highlighting the
need for vaccine development offering broad strain protection.
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1. Introduction
Group A Streptococcus (GAS) causes a significant morbidity and mortality burden
globally due to a variety of clinical manifestations and subsequent immunologically medi-
ated complications, including acute rheumatic fever (ARF) and rheumatic heart disease
(RHD) [1]. The highest burden of disease is found in low- and middle-income countries
(LMIC) although there may be considerable geographic variability [1]. Even though there
has long been a need for a GAS vaccine, recent advances are favoring its development. In
2018, the World Health Assembly supported GAS vaccine development through a renewed
action to control both ARF and RHD [2]. A global atlas of vaccine candidate antigens,
originating from a genetically diverse worldwide study of 2083 GAS genomes, was also
recently published [3]. Finally, a human challenge model of GAS acute throat infection has
been established and may enhance vaccine development [4]. The surface M protein is a
major virulence determinant, and its N-terminal amino-acid residue consists of a highly
variable amino-acid sequence that results in significant antigenic diversity (emm-types).
This was the basis for a recombinant hybrid vaccine containing M protein epitopes from
multiple GAS serotypes (i.e., the current 30-valent vaccine). The latter, together with an-
other vaccine targeting the conserved J8 region of the M protein, has so far reached phase 1
of clinical trials [2]. The 30-valent vaccine covers the most frequent serotypes circulating in
high-income countries (HIC), but concerns have been raised about its coverage in LMIC
settings where the diversity of GAS emm-types, and therefore M serotypes, is greater [5,6].
However, the pre-clinical development of the 30-valent vaccine has demonstrated in vitro
cross-opsonization against isolates expressing M proteins that are not included in the
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vaccine, suggesting that its coverage could be higher than expected [7]. The J8 vaccine
candidate was designed to offer protection against most GAS isolates by using a relatively
conserved vaccine antigen [2].
Importantly, only limited epidemiological data are currently available from many
regions, making vaccine coverage estimates imprecise. In Africa, GAS molecular data
(emm-sequence types) are reported from only five countries (Tunisia, Mali, Ethiopia, Kenya,
and South Africa), as recently reviewed [8]. The aim of the current study was to characterize
the molecular epidemiology of GAS infections in The Gambia, West Africa, and to assess
the theoretical coverage of the 30-valent vaccine candidate.
2. Material and Methods
The clinical microbiology laboratory database at the Medical Research Council The
Gambia (MRCG) at the London School of Hygiene and Tropical Medicine was interro-
gated to identify all clinical GAS isolates recorded between December 2004 and June 2018.
Invasive GAS isolates identified within the Pneumococcal Surveillance Project (PSP) (
https://www.mrc.gm/pneumococcal-surveillance-project-psp-press-briefing/) between
2008 and 2017 were also included. An invasive GAS disease was defined as the isolation
of GAS from a normally sterile body site including bacteremia/septicaemia, meningitis,
pneumonia, septic arthritis, osteomyelitis, cellulitis with septicaemia, necrotizing fasciitis,
and streptococcal toxic shock syndrome. A non-invasive GAS disease included throat and
skin infections without septicaemia.
Stored GAS isolates were retrieved from the MRCG Biobank, sub-cultured and con-
firmed using a rapid latex streptococcal grouping kit, Streptex (Remel) at the MRCG
Clinical Microbiology Laboratory, then sent to the Molecular Bacteriology Laboratory,
Brussels (MBLB), Belgium, for genotyping. The MRCG Clinical Microbiology Laboratory
is accredited to ISO 15189:2012.
At the MBLB, all isolates were reconfirmed as GAS by colony morphology, beta-
hemolysis on 5% sheep blood agar, negative catalase reaction, and detection of Lancefield
group A antigen by latex agglutination (PastorexTM Strep, Biorad, Belgium). These GAS
isolates were typed using the recently published updated emm-typing protocol [9]. The
use of this new PCR-based typing protocol improves the specificity of the emm-typing PCR
reaction using a primer called CDC3. This method therefore reduces the amplification of
multiple bands by PCR, avoiding the misclassification of strains into types based on non-
emm gene sequences [9]. In addition, we used an emm-cluster typing system that classifies
the numerous GAS emm-types into 48 discrete emm-clusters containing closely related M
proteins that share binding and structural properties [10]. The 30-valent vaccine coverage
was estimated using the latest cross-opsonization data [7,10]. The GAS strain diversity
was assessed by Simpson’s reciprocal index. The Gambia Government/MRCG Joint Ethics
Committee gave ethical approval for the conduct of the study (SCC 1567-L2018.41).
3. Results
Four hundred and thirty-three GAS isolates were identified from 431 patients, of
whom 398 presented to the MRCG outpatient department in Fajara (coastal area) between
10 December 2004 and 30 June 2018, and 33 were from the PSP study. The latter were all
from children less than five years of age (median 19 months (IQR: 15–32)) with a sex ratio
M/F of 1:4, while the former included children and adults aged from <1 month to 77 years
(median 13 years (IQR: 2–28)) with a sex ratio of 1:1. Notably, age and sex information were
only available for 152 (37.7%) and 188 (46.6%), respectively, of the 398 MRCG Fajara patients.
All GAS isolates from the PSP study were from patients with bacteremia, 12 of whom also
had pneumonia and three had meningitis. Among the 336 MRCG Fajara patients with
available clinical data, the majority (230 = 68.5%) had skin infections (mostly pyoderma),
another 20.2% (n = 69) had ear-nose-throat (ENT) infections including 39 external otitis and
22 pharyngitis, and 7.3% (n = 25) had bacteremia.
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Eighty emm-types were identified among the 433 GAS isolates, encompassing 22 emm-
clusters. Most emm-types (76.3%; n = 61) belonged to 5 emm-clusters, and of those remain-
ing, 13 emm-types represented 13 single-type clusters. Twenty-two GAS isolates were
considered non-typeable (Table 1). No novel emm-types were identified, but eight new
emm-sequences were submitted to the American Center for Disease Control (CDC) and
were identified as new subtypes (Table 1). Those new sequences have been included
in the worldwide database (https://www.cdc.gov/streplab/groupa-strep/index.html).
Simpson’s reciprocal index on emm-types was 41.6 (95% confidence interval (CI): 36.7–48.1),
indicating considerable diversity.
Table 1. emm-clusters, emm-subtypes characterized in this study (n = 433 Group A Streptococcus (GAS) isolates), and the
number of isolates by non-invasive and invasive infections (n = 371).
emm-Cluster GAS Isolates (n) emm-Types (n) NINV n (%)n = 313
INV n (%)
n = 58
E6 88 11.0 # (13), 42.0& (1), 42.3 & (4), 63.0 & (3), 65.0 & (1), 65.4 & (5), 65.7 &(22), 75.1 # (7), 75.3 # (8), 81.2 # (10), 85.1 & (7), 158.0 & (2), 182.1 (5). 67 (21.2) 10 (17.2)
E3 75
25.1& (11), 44.0 # (6), 49.0 # (8), 49.1 # (2), 49.10 # (2), 49.3 # (4), 58.0 #
(4), 58.1 # (1), 58.17 # (1), 82.6 # (4), 103.0 (4), 118.0 # (12), 180.0 & (1),
183.2 & (8), 209.3 (7)
50 (15.8) 14 (24.1)
E4 64 8.3 & (2), 28.5 # (17), 73.0 # (2), 77.0 # (15), 87.9 # (3), 88.8 * (1), 88.9 *(4),89.14 # (4), 89.8 # (2), 109.1 & (9), 169.1 & (4), 232.1 (1) 49 (15.7) 5 (8.6)
E2 31 50.0 (4), 66.1 & (2), 68.0 & (1), 90.1 (3), 92.0 # (3), 104.0 (6), 106.0 (1),110.10 (1), 166.1 (1), 166.4 (5) 168.1 & (4) 23 (7.3) 4 (6.9)
D4 31 53.1 & (3), 56.3 * (1), 80.0 (2), 86.2 (3), 93.0 (7), 119.2 (2),192.0 (1), 223.0 (2), 225.0 (3), 230.1 (7) 24 (7.6) 3 (5.2)
M95 20 95.0 & (20) 10 (3.2) 7 (12.1)
E1 13 4.0 # (1), 4.21 # (3), 4.5 # (4), 60.7 & (4), 78.6 *#(1) 10 (3.2) 0
M55 10 55.0 (10) 4 (1.3) 4 (6.9)
D2 9 71.0 & (2), 71.1 & (3), 100.3 & (4) 8 (2.5) 1 (1.7)
M19 8 19.9 # (6), 19.14 *# (1), 19.15 *# (1) 7 (2.2) 1 (1.7)
M74 9 74.0 & (9) 9 (2.8) 0
M57 6 57.0 (6) 3 (1.0) 0
M18 5 18.12 # (1), 18.21 # (4) 2 (0.6) 0
M122 4 122.0 & (4) 4 (1.3) 0
M111 4 111.1 & (4) 4 (1.3) 0
M218 4 218.1 (4) 3 (1.0) 1 (1.7)
AC4 3 229.0 (3) 2 (0.6) 0
AC5 3 31.10 *(3) 1 (0.3) 2 (3.5)
D1 2 207.0 (2) 2 (0.6) 0
M179 2 179.0 (2) 1 (0.3) 0
M26 1 26.3 (1) 1 (0.3) 0
M105 1 105.0 & (1) 1 (0.3) 0
Non-classified
for emm-cluster 40
127.0 (1), 145.4 (1), 147.0 (2), 162.1 (4), 220.0 (2), 240.1 (1), STC46 (2),
STG643.1 (2), STG866.1 (1), STG866.X2 *(1), STG7882.3 (1).
Not able to be emm-typed (22)
28 (9.0) 6 (10.3)
Not able to be emm-typed (22)
Not able to be emm-typed (22)
* New emm-subtypes identified in this study. NINV = non-invasive, INV = invasive infections. # emm-type included in the 30-valent vaccine
& emm-type cross-opsonized by 30-valent vaccine.
Excluding the non-typeable isolates, the five most frequent emm-clusters were, in
decreasing order, E6 (22.3%, 95% CI [17.9; 27.4]), followed by E3 (19.0%, 95%CI [14.9;
23.8]), then E4 (16.5%, 95%CI [12.7; 21.0]), and E2 and D4 (each at 7.9%, 95%CI [5.3; 11.1]),
encompassing 66% of The Gambia isolates (Table 1). There was evidence for a different
emm-cluster distribution among non-invasive and invasive infections. Indeed, among
invasive infections, the most predominant cluster was E3 (24.1%), followed by E6 (17.2%),
then M95 (12.1%), E4 (8.9%), and E2 and M55 (each 6.9%) (exact test for difference between
invasive infections (INV) and non invasive infections (NINV), p-value = 0.03). Based on
published vaccine ELISA data [7,10], 150 isolates (34.6%) were emm-types included by the
30-valent vaccine, and an additional 141 isolates (32.6%) might be covered by the vaccine
because of in vitro cross-opsonization. Therefore, the potential coverage could be expected
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to be 67.2% (95% CI 62.8–71.6%) but may be higher, as 29.6% of the isolates belonged to
37 emm-types which have not yet been examined for cross-opsonization.
4. Discussion
These data are the first to be published on Group A Streptococcus molecular epidemiol-
ogy in The Gambia. We observed a high level of diversity of GAS strains associated with
invasive disease, skin, and throat infections. Although eight new subtypes were identified
by this study, no new emm-types were discovered, suggesting that the CDC reference
laboratory may have good coverage in terms of emm-type diversity. The emm-type in
Simpson’s reciprocal index was 41.6 indicating considerable diversity, a result similar to
that seen in other African studies [8]. The predominant emm-clusters identified in our
study were similar to those reported in the recently published systematic review that
included five African countries [8] but were different from high income countries such
as the United States, where E4, AC3, and AC4 were the most predominant clusters [11].
Furthermore, the different emm-cluster distributions found among non-invasive infections,
with a predominance of E6, and invasive infections, with a predominance of E3 followed by
E6, were also reported in other African studies [8]. Additionally, two single-type clusters,
M55 and M95, that were specifically found in Mali [8] were also relatively common in our
study (respectively, n = 10 and 20 isolates), suggesting that similarity in GAS circulation
may exist. Non-typable isolates are likely to be related to limitations in the emm-typing
methods [9] or, rather exceptionally, be associated with emm-negative strains [3].
Over two third of our isolates (including non-typeables (NTs)) were potentially cov-
ered by the current 30-valent vaccine because of potential cross-opsonization, and this
figure could be higher if the 37 uninvestigated emm-types show cross-opsonization. This
highlights the importance and urgent need to further investigate the potential for cross-
opsonization for the pending 37 emm-types to better estimate the coverage of the 30-valent
vaccine both in invasive and non-invasive isolates in The Gambia. A review of African
studies showed a potential coverage of 80% of isolates after including those potentially
covered by the vaccine as a result of cross-opsonization; however, the coverage would
have been only 56% if the emm-types covered by the vaccine were taken into account [8].
On the other hand, cross-opsonization in vitro still needs to be assessed in human studies,
hence these results must be interpreted cautiously. Vaccine antigen development should
definitively aim for the broadest strain coverage possible.
The main limitation of this study was its retrospective design, which was prone to data
incompleteness, lack of accuracy, as well as methodological bias. Indeed, our data suffered
from a substantial amount of missing and incomplete information on socio-demographic
and clinical presentations, which prevented any meaningful analysis of the emm-cluster
distribution by age, sex, geographical location, or clinical presentation. Going forward, the
MRC Clinical Services has now instituted an electronic data capture system to avoid such
problems in the future. In addition, compared with the vast majority of skin samples, acute
throat infections were likely largely under-represented in our study since they are rarely
considered worthy of seeking medical treatment in The Gambia [12]. This could have
negatively affected the frequency of some emm-types specific to this presentation, if any.
Further community-based studies on the molecular epidemiology of Strep A pharyngitis in
The Gambia are needed to provide more insights on this aspect. Nevertheless, the fact that
our molecular typing results are very similar to those published by a systematic review of
eight prospective studies across Africa, including different age groups and presentations,
supports their wider validity.
Overall, these data indicate a high diversity of circulating GAS strains in The Gam-
bia, and the urgent need for complementary studies to assess the potential coverage of
the 30-valent vaccine candidate. These results highlight the need for robust regional
and country-level data to inform future vaccine design. Moving forward, a prospective
and comprehensive GAS infection surveillance in The Gambia and in Africa would be
highly desirable.
Vaccines 2021, 9, 0 5 of 6
Author Contributions: A.E., M.A., P.R.S. and G.M. designed the study, coordinated its implementa-
tion, analyzed and interpreted the data, contributed to the literature review, writing and review of
the paper; S.D., A.-K.B. screened and revived all GAS isolates at MRCG, confirmed the pathogen
and organized the shipment for genotyping, they reviewed the first manuscript and approved the
final version; V.D. and A.B. revived isolates in Belgium, confirmed diagnosis, did the genotyping
and data analysis, they reviewed the first draft of the manuscript and approved the final version
before submitting to the journal; G.W. and E.F.-N. contributed in providing the metadata, reviewed
for the first draft and approved the last version of the manuscript; R.S. was involved in the screening
and isolation of GAS from the clinical specimen, he reviewed first manuscript and approved the
last version before submitting to the Journal; B.L. supervised the lab work at MRCG, he reviewed
the first draft and approved the last draft of the manuscript before submission to the journal; S.J.
retrieved and collated all metadata, contributed to the data analysis, literature search, writing of
the manuscript, reviewing and finalizing the manuscript. All authors have read and agreed to the
published version of the manuscript.
Funding: This study was funded by a Wellcome Trust Seed Award [206061/Z17Z].
Institutional Review Board Statement: The study has been approved by the Gambian Government-
MRCG Joint Ethics Committee (SCC1567-L2018.41).
Informed Consent Statement: Prior consent for secondary analysis of stored samples had previously
been obtained during the PSP project. Ethical clearance was obtained from the Gambian Government
for the secondary analysis of the GAS isolates from the clinical microbiology laboratory stored at the
MRCG biobank.
Data Availability Statement: Data are available at the MRCG at LSHTM and be made available
upon request to the corresponding author.
Acknowledgments: We would like to thank the invaluable contribution and strong support of
the members of the MRCG Strep A Study Group whose names are not in the main authorship
list: Abdul Karim Sesay; Saikou Y. Bah; Claire E. Turner; Thushan De Silva; Beate Kampmann;
Suzanne Anderson; Anna Roca; Isatou Jagne Cox; Peggy-Estelle Tiencheu; Edwin-Peter Armitage;
Alexander Keeley.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Watkins, D.A.; Johnson, C.O.; Colquhoun, S.M.; Karthikeyan, G.; Beaton, A.; Bukhman, G.; Forouzanfar, M.H.; Longenecker, C.T.;
Mayosi, B.M.; Mensah, G.A.; et al. Global, Regional, and National Burden of Rheumatic Heart Disease, 1990–2015. N. Engl. J. Med.
2017, 377, 713–722. [CrossRef] [PubMed]
2. Vekemans, J.; Gouvea-Reis, F.; Kim, J.H.; Excler, J.L.; Smeesters, P.R.; O’Brien, K.L.; Kaslow, D.C. The path to group A Streptococcus
vaccines: WHO research and development technology roadmap and preferred product characteristics. Clin. Infect. Dis. 2019,
69, 877–883. [CrossRef] [PubMed]
3. Davies, M.R.; McIntyre, L.; Mutreja, A.; Lacey, J.A.; Lees, J.A.; Towers, R.J.; Duchêne, S.; Smeesters, P.R.; Frost, H.R.; Price, D.J.;
et al. Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics. Nat. Genet. 2019,
51, 1035–1043. [CrossRef] [PubMed]
4. Osowicki, J.; Azzopardi, K.I.; Baker, C.; Waddington, C.S.; Pandey, M.; Schuster, T.; Grobler, A.; Cheng, A.C.; Pollard, A.J.;
McCarthy, J.; et al. Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A
Streptococcus pharyngitis human infection study. Vaccine 2019, 37, 3485–3494. [CrossRef] [PubMed]
5. Steer, A.C.; Law, I.; Matatolu, L.; Beall, B.W.; Carapetis, J.R. Global emm type distribution of group A streptococci: Systematic
review and implications for vaccine development. Lancet Infect. Dis. 2009, 9, 611–616. [CrossRef]
6. Smeesters, P.R.; McMillan, D.J.; Sriprakash, K.S.; Georgousakis, M.M. Differences among group A streptococcus epidemiological
landscapes: Consequences for M protein-based vaccines? Expert Rev. Vaccines 2009, 8, 1705–1720. [CrossRef]
7. Dale, J.B.; Fischetti, V.A.; Carapetis, J.R.; Steer, A.C.; Sow, S.; Kumar, R.; Mayosi, B.M.; Rubin, F.A.; Mulholland, K.; Hombach,
J.M.; et al. Group A streptococcal vaccines: Paving a path for accelerated development. Vaccine 2013, 31 (Suppl. 2), B216–B222.
[CrossRef]
8. Salie, T.; Engel, K.; Moloi, A.; Muhamed, B.; Dale, J.B.; Engel, M.E. Systematic review and meta-analysis of the prevalence of Strep
A emm clusters in Africa to inform vaccine development. mSphere 2020, 5, e00429-20. [CrossRef] [PubMed]
9. Frost, H.R.; Davies, M.R.; Velusamy, S.; Delforge, V.; Erhart, A.; Darboe, S.; Steer, A.; Walker, M.J.; Beall, B.; Botteaux, A.; et al.
Updated emm-typing protocol for Streptococcus pyogenes. Clin. Microbiol. Infect. 2020, 26, 946.e5–946.e8. [CrossRef] [PubMed]
10. Sanderson-Smith, M.; De Oliveira, D.M.P.; Guglielmini, J.; McMillan, D.J.; Vu, T.; Holien, J.K.; Henningham, A.; Steer, A.C.;
Bessen, D.E.; Dale, J.B.; et al. A Systematic and Functional Classification of Streptococcus pyogenes That Serves as a New Tool for
Molecular Typing and Vaccine Development. J. Infect. Dis. 2014, 210, 1325–1338. [CrossRef] [PubMed]
Vaccines 2021, 9, 0 6 of 6
11. Shulman, S.T.; Tanz, R.R.; Dale, J.B.; Steer, A.C.; Smeesters, P.R. Added Value of the emm-Cluster Typing System to Analyze
Group A Streptococcus Epidemiology in High-Income Settings. Clin. Infect. Dis. 2014, 59, 1651–1652. [CrossRef] [PubMed]
12. Jaiteh, D.L.; Anderson, S.T.; Mendy, J.; Ceesay, S.; D’Alessandro, U.; Carapetis, J.; Mirabel, M.; Erhart, A. Rheumatic Heart Disease
in The Gambia: Clinical and valvular aspects at presentation and evolution under penicillin prophylaxis. JAHA. (under review).
